French National Reference Center for Campylobacters and Helicobacters, Bordeaux Hospital University Center, Bordeaux, France.
University Bordeaux, INSERM, UMR1312 Bordeaux Institute of Cancer, BRIC, Bordeaux, France.
Microbiol Spectr. 2022 Aug 31;10(4):e0100322. doi: 10.1128/spectrum.01003-22. Epub 2022 Jul 7.
Aliarcobacter butzleri is an emerging gastrointestinal pathogen found in many countries worldwide. In France, it has become the third most commonly isolated bacterial species from the stools of patients with intestinal infections. No interpretative criteria for antimicrobial susceptibility testing have been proposed for A. butzleri, and most strains are categorized using the recommendations of the Clinical and Laboratory Standards Institute or the European Committee on Antimicrobial Susceptibility Testing for Campylobacter or . In the present study, the genomes of 30 resistant A. butzleri isolates were analyzed to propose specific epidemiological cut-off values for ampicillin, ciprofloxacin, erythromycin, and tetracycline. The identification of a β-lactamase and the T85I GyrA mutation associated with ampicillin and ciprofloxacin resistance, respectively, allowed us to adjust the disk diffusion (DD) and MIC cut-off values for these molecules. However, epidemiological cut-off values for erythromycin and tetracycline could not be estimated due to the absence of known resistance mechanisms. The present study paves the way for building a consensus for antimicrobial susceptibility testing for this concerning pathogen. Aliarcobacter butzleri is an emerging and concerning intestinal pathogen. Very few studies have focused on this particular species, and antimicrobial susceptibility testing (AST) is based on methods that have been mostly developed for Campylobacter spp. In fact, no disk diffusion and E-tests adapted cut-offs for A. butzleri are available which leads to misinterpretations. We have shown here that NGS approach to identify genes and mutations in close relation to phenotypic resistance levels is a robust way to solve that issue and precisely differentiate WT and NWT A. butzleri isolates for frequently used antimicrobials. MIC and DD cut-off values have been significantly adjusted and answer the need for a global consensus regarding AST for A. butzleri.
Aliarcobacter butzleri 是一种新兴的胃肠道病原体,在世界许多国家都有发现。在法国,它已成为从肠道感染患者粪便中分离出的第三大最常见细菌。目前尚未提出针对 A. butzleri 的抗菌药物敏感性测试解释标准,大多数菌株使用临床和实验室标准协会或欧洲抗菌药物敏感性测试委员会针对弯曲杆菌或 的建议进行分类。在本研究中,分析了 30 株耐药 A. butzleri 分离株的基因组,以提出针对氨苄西林、环丙沙星、红霉素和四环素的特定流行病学折点值。β-内酰胺酶和与氨苄西林和环丙沙星耐药相关的 T85I GyrA 突变的鉴定,使我们能够调整这些分子的纸片扩散(DD)和 MIC 折点值。然而,由于缺乏已知的耐药机制,无法估计红霉素和四环素的流行病学折点值。本研究为建立针对这种令人关注的病原体的抗菌药物敏感性测试共识铺平了道路。Aliarcobacter butzleri 是一种新兴的令人关注的肠道病原体。很少有研究关注这种特殊的物种,抗菌药物敏感性测试(AST)是基于主要为弯曲杆菌属开发的方法。事实上,没有针对 A. butzleri 的适应折点的纸片扩散和 E 试验可用,这导致了错误的解释。我们在这里表明,用于鉴定与表型耐药水平密切相关的基因和突变的 NGS 方法是解决该问题的一种可靠方法,可以精确地区分 WT 和 NWT A. butzleri 分离株对常用抗菌药物的耐药性。MIC 和 DD 折点值已显著调整,满足了针对 A. butzleri 的 AST 建立全球共识的需求。